Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

fatigue treatments

Sanofi reception

Sanofi’s oral therapy Aubagio approved in the EU for paediatric MS patients

EC approval comes a few weeks after the FDA rejected Aubagio in the same patient population

Biogen Idec building

Biogen reveals new data for MS therapies Tysabri and Vumerity

New data comes ahead of FDA decision on company's controversial Alzheimer’s drug aducanumab

Roche Basel Switzerland

Roche’s Ocrevus shows significant benefit in early-stage MS patients

The data was presented virtually at the American Academy of Neurology annual meeting

Novartis day

Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses

New post hoc data comes from phase 3 ASCLEPIOS trials

- PMLiVE

Novartis gains EU approval for relapsing MS drug Kesimpta

The drug reduces the number of confirmed relapses in MS patients

- PMLiVE

J&J’s multiple sclerosis therapy Ponvory moves closer to EU approval

CHMP issues a positive opinion for S1P1 modulator based on positive phase 3 results

- PMLiVE

J&J’s MS drug ponesimod receives approval in the US

US regulator has approved the drug – now named Ponvory – for relapsing forms of MS

Covid-19: how is it affecting prescribing patterns?

Oli Hudson, Content Director at Wilmington Healthcare, analyses prescribing data in three key disease areas

Wilmington Healthcare

Biogen Idec building

New intramuscular administration for Biogen’s MS therapy Plegridy approved in the EU

New administration offers same efficacy as subcutaneous injection

- PMLiVE

Novartis’ MS therapy Mayzent approved by NICE

Agency approves drug after new cost-effectiveness proposal

- PMLiVE

Roche’s Ocrevus boasts positive long-term data in MS

After two years of treatment 75% of patients had no evidence of disease activity

- PMLiVE

Novartis wins FDA approval for relapsing MS drug Kesimpta

Swiss pharma company is expecting EU approval for treatment next year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links